PT886 For Treatment of Patients With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

• Status: Not yet recruiting
• Trial end date: 2024-01-01

Summary

PT886 is a novel bispecific antibody that targets Claudin 18.2 and CD47. Claudin 18.2 is overexpressed in a significant proportion of gastric, esophageal, and pancreatic adenocarcinomas and its restricted expression makes it a promising therapeutic target for the treatment of these carcinomas. Moreover, studies have found that immunoglobulin superfamily CD47 is overexpressed widely across tumor types, and CD47 plays an important role in suppressing phagocytes activity through binding to the transmembrane protein SIRPα in phagocytic cells. Hence by targeting both pathways, one can direct macrophage-mediated phagocytotic activity to tumor cells by blocking the "don't eat me signal" mediated by CD47/ SIRPα interaction, potentially offering a better safety profile than anti-CD47 monoclonal antibodies.

This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PT886 in subjects with advanced or refractory cancers.

Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC) for which there is no available standard therapy.

• Phase: Phase 1

Details

• Lead Sponsor: Phanes Therapeutics